Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.6600 (6.69%) ($7.1200 - $8.3500) on Tue. Mar. 17, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.78% (three month average) | RSI | 30 | Latest Price | $7.6600(6.69%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -7.6% a day on average for past five trading days. | Weekly Trend | TGTX declines -20% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(66%) ARKG(61%) IBB(59%) ARKK(58%) IWO(58%) | Factors Impacting TGTX price | TGTX will decline at least -2.89% in a week (0% probabilities). VIXM(-40%) VXX(-39%) UUP(-7%) TLT(-6%) IGOV(1%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.89% (StdDev 5.78%) | Hourly BBV | 0 () | Intraday Trend | 4.5% | | | |
|
1 - 5 Day Possible Target | $-26.75(-449.22%) | Resistance Level | $12.09 | 5 Day Moving Average | $8.39(-8.7%) | 10 Day Moving Average | $10.06(-23.86%) | 20 Day Moving Average | $12.09(-36.64%) | To recent high | -52.1% | To recent low | 6.7% | Market Cap | $970m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |